Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The cutaneous T-cell lymphoma clinical trial analysis ...

Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies. When the Swiss pharma unveiled the ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis." Normally, a B cell ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

Autologous stem-cell transplantation (ASCT) has remained central to the care of younger patients with mantle cell lymphoma since the publication of the first European Mantle Cell Lymphoma Network ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...